Uncovering SUMOylation dynamics during cell-cycle progression reveals foxM1 as a key mitotic SUMO target protein

Molecular Cell

Volumn 53, Issue 6, 2014, Pages 1053-1066

  Schimmel, Joost ^a   Eifler, Karolin ^a   Sigursson, JónOtti ^b   Cuijpers, Sabine A G ^a   Hendriks, Ivo A ^a   Verlaan de Vries, Matty ^a   Kelstrup, Christian D ^b   Francavilla, Chiara ^b   Medema, René H ^c   Olsen, Jesper V ^b   Vertegaal, Alfred C O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University of Copenhagen   (Denmark)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR PROTEIN; PROTEIN UBA2; PROTEIN UBC9; SUMO 2 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; AURORA B KINASE; CENP F PROTEIN; CYCLIN B1; GLUTATHIONE; GLUTATHIONE TRANSFERASE; PROTEIN; SAP30 PROTEIN; SHORT HAIRPIN RNA; SUMO PROTEIN; UBA2 PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME SEGREGATION; COLONY FORMATION; CONTROLLED STUDY; DIMERIZATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYMERIZATION; POLYPLOIDY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SUMOYLATION; CHROMOSOME CONDENSATION; COMPARATIVE STUDY; ENZYME ACTIVITY; GENE ONTOLOGY; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; MITOSIS; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN TARGETING; SUMOYLATION DYNAMICS; WILD TYPE;

MUS;

AMINO ACID SEQUENCE; CELL CYCLE; CHROMOSOME SEGREGATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; TRANSCRIPTION, GENETIC;

EID: 84896387847     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.02.001     Document Type: Article

References (50)

1. Anders L., Ke N., Hydbring P., Choi Y.J., Widlund H.R., Chick J.M., Zhai H., Vidal M., Gygi S.P., Braun P., Sicinski P. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011, 20:620-634.
2. Armstrong A.A., Mohideen F., Lima C.D. Recognition of SUMO-modified PCNA requires tandem receptor motifs in Srs2. Nature 2012, 483:59-63.
3. Becker J., Barysch S.V., Karaca S., Dittner C., Hsiao H.H., Berriel Diaz M., Herzig S., Urlaub H., Melchior F. Detecting endogenous SUMO targets in mammalian cells and tissues. Nat. Struct. Mol. Biol. 2013, 20:525-531.
4. Bettermann K., Benesch M., Weis S., Haybaeck J. SUMOylation in carcinogenesis. Cancer Lett. 2012, 316:113-125.
5. Choudhary C., Mann M. Decoding signalling networks by mass spectrometry-based proteomics. Nat. Rev. Mol. Cell Biol. 2010, 11:427-439.
6. Dawlaty M.M., Malureanu L., Jeganathan K.B., Kao E., Sustmann C., Tahk S., Shuai K., Grosschedl R., van Deursen J.M. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 2008, 133:103-115.
7. Fisher D., Krasinska L., Coudreuse D., Novák B. Phosphorylation network dynamics in the control of cell cycle transitions. J.Cell Sci. 2012, 125:4703-4711.
8. Flotho A., Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 2013, 82:357-385.
9. Gareau J.R., Lima C.D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 2010, 11:861-871.
10. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
11. Halasi M., Gartel A.L. Targeting FOXM1 in cancer. Biochem. Pharmacol. 2013, 85:644-652.
12. Hay R.T. SUMO: a history of modification. Mol. Cell 2005, 18:1-12.
13. Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J., Nakai A., Sistonen L. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. USA 2006, 103:45-50.
14. Hsiao H.H., Meulmeester E., Frank B.T., Melchior F., Urlaub H. "ChopNSpice," a mass spectrometric approach that allows identification of endogenous small ubiquitin-like modifier-conjugated peptides. Mol. Cell. Proteomics 2009, 8:2664-2675.
15. Kirkin V., Dikic I. Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr. Opin. Cell Biol. 2007, 19:199-205.
16. Kirkin V., Dikic I. Ubiquitin networks in cancer. Curr. Opin. Genet. Dev. 2011, 21:21-28.
17. Klein U.R., Haindl M., Nigg E.A., Muller S. RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation-deconjugation cycle on Borealin. Mol. Biol. Cell 2009, 20:410-418.
18. Koo C.Y., Muir K.W., Lam E.W. FOXM1: From cancer initiation to progression and treatment. Biochim. Biophys. Acta 2012, 1819:28-37.
19. Laoukili J., Kooistra M.R., Brás A., Kauw J., Kerkhoven R.M., Morrison A., Clevers H., Medema R.H. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005, 7:126-136.
20. Laoukili J., Alvarez M., Meijer L.A., Stahl M., Mohammed S., Kleij L., Heck A.J., Medema R.H. Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. Mol. Cell. Biol. 2008, 28:3076-3087.
21. Laoukili J., Alvarez-Fernandez M., Stahl M., Medema R.H. FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner. Cell Cycle 2008, 7:2720-2726.
22. Li S.J., Hochstrasser M. A new protease required for cell-cycle progression in yeast. Nature 1999, 398:246-251.
23. López-Otín C., Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat. Rev. Cancer 2010, 10:278-292.
24. Lyst M.J., Stancheva I. A role for SUMO modification in transcriptional repression and activation. Biochem. Soc. Trans. 2007, 35:1389-1392.
25. Mann M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 2006, 7:952-958.
26. Matic I., van Hagen M., Schimmel J., Macek B., Ogg S.C., Tatham M.H., Hay R.T., Lamond A.I., Mann M., Vertegaal A.C. Invivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an invitro to invivo strategy. Mol. Cell. Proteomics 2008, 7:132-144.
27. Matic I., Schimmel J., Hendriks I.A., van Santen M.A., van de Rijke F., van Dam H., Gnad F., Mann M., Vertegaal A.C. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol. Cell 2010, 39:641-652.
28. Mukhopadhyay D., Arnaoutov A., Dasso M. The SUMO protease SENP6 is essential for inner kinetochore assembly. J.Cell Biol. 2010, 188:681-692.
29. Myatt S.S., Kongsema M., Man C.W., Kelly D.J., Gomes A.R., Khongkow P., Karunarathna U., Zona S., Langer J.K., Dunsby C.W., et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene 2013, Published online December 23, 2013. 10.1038/onc.2013.546.
30. Nacerddine K., Lehembre F., Bhaumik M., Artus J., Cohen-Tannoudji M., Babinet C., Pandolfi P.P., Dejean A. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev. Cell 2005, 9:769-779.
31. Neyret-Kahn H., Benhamed M., Ye T., Le Gras S., Cossec J.C., Lapaquette P., Bischof O., Ouspenskaia M., Dasso M., Seeler J., et al. Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation. Genome Res. 2013, 23:1563-1579.
32. Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci. Signal. 2010, 3:ra3.
33. Ouyang J., Valin A., Gill G. Regulation of transcription factor activity by SUMO modification. Methods Mol. Biol. 2009, 497:141-152.
34. Park H.J., Wang Z., Costa R.H., Tyner A., Lau L.F., Raychaudhuri P. An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle. Oncogene 2008, 27:1696-1704.
35. Psakhye I., Jentsch S. Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. Cell 2012, 151:807-820.
36. Radhakrishnan S.K., Bhat U.G., Hughes D.E., Wang I.C., Costa R.H., Gartel A.L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006, 66:9731-9735.
37. Saitoh H., Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J.Biol. Chem. 2000, 275:6252-6258.
38. Schwartz D.C., Felberbaum R., Hochstrasser M. The Ulp2 SUMO protease is required for cell division following termination of the DNA damage checkpoint. Mol. Cell. Biol. 2007, 27:6948-6961.
39. Seufert W., Futcher B., Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 1995, 373:78-81.
40. Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M., Botting C.H., Naismith J.H., Hay R.T. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J.Biol. Chem. 2001, 276:35368-35374.
41. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., Hay R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 2008, 10:538-546.
42. Ulrich H.D. Regulating post-translational modifications of the eukaryotic replication clamp PCNA. DNA Repair (Amst.) 2009, 8:461-469.
43. Vertegaal A.C. Uncovering ubiquitin and ubiquitin-like signaling networks. Chem. Rev. 2011, 111:7923-7940.
44. Vertegaal A.C., Ogg S.C., Jaffray E., Rodriguez M.S., Hay R.T., Andersen J.S., Mann M., Lamond A.I. A proteomic study of SUMO-2 target proteins. J.Biol. Chem. 2004, 279:33791-33798.
45. Wan J., Subramonian D., Zhang X.D. SUMOylation in control of accurate chromosome segregation during mitosis. Curr. Protein Pept. Sci. 2012, 13:467-481.
46. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005, 25:10875-10894.
47. Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv. Cancer Res. 2013, 119:191-419.
48. Zhang X.D., Goeres J., Zhang H., Yen T.J., Porter A.C., Matunis M.J. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol. Cell 2008, 29:729-741.
49. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.
50. Zhao F., Lam E.W. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Front Med. 2012, 6:376-380.